Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 13
Submit an article Journal homepage
5,329
Views
25
CrossRef citations to date
0
Altmetric
Original Articles

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Graeme A.M. Frasera Juravinski Cancer Centre, McMaster University, Hamilton, CanadaCorrespondence[email protected]
,
Asher Chanan-Khanb Division of Hematology, Mayo Clinic Cancer Center, Jacksonville, FL, USA
,
Fatih Demirkanc Division of Hematology, Dokuz Eylul University, Izmir, Turkey
,
Rodrigo Santucci Silvad IEP São Lucas/Hemomed Oncologia e Hematologia, São Paulo, Brazil
,
Sebastian Grosickie Department of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland
,
Ann Janssensf Universitaire Ziekenhuizen Leuven, Leuven, Belgium
,
Jiri Mayerg Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Jihlavska, Brno, Czech Republic
,
Nancy L. Bartletth Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USAORCID Iconhttps://orcid.org/0000-0001-8470-394X
ORCID Icon,
Marie-Sarah Dilhuydyi Hopital Haut Leveque, Bordeaux, France
,
Javier Loscertalesj Hematology Department, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain
,
Abraham Avigdork Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel
,
Simon Rulel Department of Haematology, University of Plymouth Medical School, Plymouth, UKORCID Iconhttps://orcid.org/0000-0001-8937-6351
ORCID Icon,
Olga Samoilovam Nizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia
,
Miguel A. Pavlovskyn Department of Hematology, Fundaleu, Buenos Aires, Argentina
,
Andre Goyo John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Anthony Matop Memorial Sloan-Kettering Cancer Center, NY, USA
,
Michael Hallekq Department I of Internal Medicine and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany
,
Mariya Salmanr Janssen Research & Development, Raritan, NJ, USA
,
Monelle Tamegnonr Janssen Research & Development, Raritan, NJ, USA
,
Steven Sunr Janssen Research & Development, Raritan, NJ, USA
,
Anne Connors Janssen Research & Development, Spring House, PA, USA
,
Kerri Nottager Janssen Research & Development, Raritan, NJ, USA
,
Natasha Schuiert Janssen-Cilag, Neuss, Germany
,
Sriram Balasubramanians Janssen Research & Development, Spring House, PA, USA
,
Angela Howesu Janssen Research & Development, High Wycombe, UK
&
Paula Cramerq Department I of Internal Medicine and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany
 show all
Pages 3188-3197 | Received 08 Apr 2020, Accepted 05 Jul 2020, Published online: 06 Aug 2020

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Laura M. Roccograndi, Alexandra R. Lovell, Alessandra Ferrajoli, Philip A. Thompson, Jan A. Burger, William G. Wierda, Nitin Jain & Caitlin R. Rausch. (2023) Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leukemia & Lymphoma 64:9, pages 1554-1561.
Read now
Danling Gu, Jianyong Li & Yi Miao. (2022) Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China. Expert Opinion on Pharmacotherapy 23:18, pages 1979-1986.
Read now

Articles from other publishers (23)

Hege Michiels, An Vandebosch & Stijn Vansteelandt. (2023) Adjusting for time-varying treatment switches in randomized clinical trials: the danger of extrapolation and how to address it. Statistics in Biopharmaceutical Research, pages 1-23.
Crossref
Nazanin Aghel, Rocio C. Baro Vila, Michelle Lui, Christopher Hillis & Darryl P. Leong. (2023) Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors. Current Cardiology Reports 25:9, pages 941-958.
Crossref
Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn, Carol Moreno, Susan M. O'Brien, Daniel Jones, Leo W.K. Cheung, Elizabeth Chong, Kevin Kwei, James P. Dean, Danelle F. James & Adrian Wiestner. (2023) B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clinical Cancer Research 29:16, pages 3065-3073.
Crossref
Fausto Alfredo Rios-Olais & Talal Hilal. (2023) Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice. Current Treatment Options in Oncology 24:8, pages 907-928.
Crossref
Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, Laura Morrison, Frederic Kinkead, Patrick Lefebvre, Marie-Hélène Lafeuille, Wasiulla Khan, Linda H Wu, Zaina P Qureshi & Moshe Yair Levy. (2023) Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib. Future Oncology.
Crossref
Tereza Líkařová & Martin Špaček. (2023) Bruton's tyrosine kinase inhibitors and their current status in the treatment of chronic lymphocytic leukemia. Onkologie 17:3, pages 192-196.
Crossref
Javier Muñoz, Shayna Sarosiek & Jorge J Castillo. (2023) Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. The Oncologist 28:4, pages 309-318.
Crossref
Philip Lee, Kristin D. Kistler, Luc Douyon, Raisa Volodarsky, Alex Young, Sudeep Karve & Swetha Challagulla. (2022) Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Drugs - Real World Outcomes 10:1, pages 11-22.
Crossref
Toshio Shimizu, Kazuhiko Nakagawa, Hidetoshi Hayashi, Tsutomu Iwasa, Hisato Kawakami, Satomi Watanabe, Noboru Yamamoto, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Keiichi Kikuchi, Kenichiro Akaike, Shiho Takeda & Masayuki Takeda. (2022) Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study. Investigational New Drugs 41:1, pages 1-12.
Crossref
Aqu Alu, Hong Lei, Xuejiao Han, Yuquan Wei & Xiawei Wei. (2022) BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology 15:1.
Crossref
Daniel Rivera & Alessandra Ferrajoli. (2022) Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies. Current Oncology Reports 24:8, pages 1003-1014.
Crossref
Hrvoje Lalic, Igor Aurer, Drago Batinic, Dora Visnjic, Tomislav Smoljo & Antonija Babic. (2022) Bendamustine: a review of pharmacology, clinical use and immunological effects (Review). Oncology Reports 47:6.
Crossref
Toby A. Eyre, Satoshi Hori & Talha Munir. (2021) Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. Hematological Oncology 40:2, pages 129-159.
Crossref
Seval Akpinar, Mehmet Hilmi Dogu, Serhat Celik, Omer Ekinci, Ipek Yonal Hindilerden, Mehmet Sinan Dal, Eren Arslan Davulcu, Atakan Tekinalp, Fehmi Hindilerden, Busra Gokce Ozcan, Tuba Hacibekiroglu, Mehmet Ali Erkurt, Metin Bagci, Sinem Namdaroglu, Gulten Korkmaz, Oktay Bilgir, Gulsum Akgun Cagliyan, Hacer Berna Afacan Ozturk, Istemi Serin, Tarık Onur Tiryaki, Duzgun Ozatli, Serdal Korkmaz, Turgay Ulas, Bulent Eser, Burhan Turgut & Fevzi Altuntas. (2022) The Real‐World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL. Clinical Lymphoma Myeloma and Leukemia 22:3, pages 169-173.
Crossref
Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. Pagel, Chaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour & Jennifer A. Woyach. (2022) Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare). Clinical Cancer Research 28:4, pages 603-608.
Crossref
John N. Allan, Tait Shanafelt, Adrian Wiestner, Carol Moreno, Susan M. O’Brien, Jianling Li, Gabriel Krigsfeld, James P. Dean & Inhye E. Ahn. (2021) Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials . British Journal of Haematology 196:4, pages 947-953.
Crossref
Juha Ranti, Katariina Perkonoja, Tommi Kauko, Heidi Loponen, Emmi I. Joensuu & Tiina M. Järvinen. (2021) Characterization of real‐world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center. eJHaem 3:1, pages 291-300.
Crossref
Alexandra R. Lovell, Nadya Jammal & Prithviraj Bose. (2022) Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations. Therapeutic Advances in Hematology 13, pages 204062072211165.
Crossref
Matt Shirley. (2021) Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features. Targeted Oncology 17:1, pages 69-84.
Crossref
Nil Albiol, Miguel Arguello-Tomas & Carol Moreno. (2021) The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. Current Opinion in Oncology 33:6, pages 670-680.
Crossref
David Allsup, Dena Howard, Jake Emmerson, Anna Hockaday, Andy Rawstron, Jamie B. Oughton, Adrian Bloor, David Phillips, Amit Nathwani, Shankara Paneesha, Deborah Turner, Talha Munir & Peter Hillmen. (2021) COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology 194:3, pages 646-650.
Crossref
Nil Albiol & Carol Moreno. (2021) Autoimmune Cytopenia in CLL. The Cancer Journal 27:4, pages 286-296.
Crossref
Inhye E. Ahn & Jennifer R. Brown. (2021) Targeting Bruton’s Tyrosine Kinase in CLL. Frontiers in Immunology 12.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.